EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of a patient by administering an antibody that inhibits cathepsin O



Treatment of a patient by administering an antibody that inhibits cathepsin O



Official Gazette of the United States Patent & Trademark Office Patents 1264(1), Nov 5



Disclosed is a human osteoclast-derived cathepsin (Cathepsin O) polypeptide and DNA(RNA) encoding such cathepsin O polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques. The present invention also discloses antibodies, antagonists and inhibitors of such polypeptide which may be used to prevent the action of such polypeptide and therefore may be used therapeutically to treat bone diseases such as osteoporosis and cancers, such as tumor metastases. A patient is treated by administering an antibody produced against a polypeptide consisting of SEQ ID NO: 2.

(PDF 0-2 workdays service: $29.90)

Accession: 035980680

Download citation: RISBibTeXText



Related references

A peptide antibody that specifically inhibits cathepsin L. Advances in Experimental Medicine and Biology 303: 285-288, 1991

Antibody targeting of cathepsin S inhibits angiogenesis and synergistically enhances anti-VEGF. Plos One 5(9): -, 2011

Cathepsin B-specific mouse monoclonal antibody inhibits MCF-10A neoT cell invasion. Anticancer Research 22(6C): 4321, November-December, 2002

Brefeldin A inhibits the targeting of cathepsin D and cathepsin H to lysosomes in rat hepatocytes. Biochemical and Biophysical Research Communications 163(1): 220-225, 1989

Innovations in administering a day treatment program. 3. Effects on patient care. Hospital & Community Psychiatry 19(6): 184-185, 1968

When, and on what basis, do physicians decide to ignore a patient's choice in favor of administering a treatment involuntarily?. Journal of the Medical Association of Georgia 98(4): 22-23, 2010

An antibody against a cathepsin B-derived synthetic peptide localizes capillaries and small blood vessels in human prostate Possible role of cathepsin B in angiogenesis. Molecular Biology of the Cell 4(SUPPL ): 337A, 1993

Implanting and fixing a flexible probe for administering a medical therapy at a treatment site within a patient body. Official Gazette of the United States Patent & Trademark Office Patents 1211(3): 2683, June 16, 1998

Anti-CD25 antibody treatment of mice vaccinated and challenged with Borrelia spp. does not exacerbate arthritis but inhibits borreliacidal antibody production. Clinical and Vaccine Immunology 13(8): 884-891, 2006

Treatment with oxLDL antibody reduces cathepsin S expression in atherosclerosis via down-regulating ADAR1-mediated RNA editing. International Journal of Cardiology: -, 2016

Fsn0503h antibody-mediated blockade of cathepsin S as a potential therapeutic strategy for the treatment of solid tumors. Biochimie 108: 101-107, 2015

Treatment with a human recombinant monoclonal IgG antibody against oxidized LDL in atherosclerosis-prone pigs reduces cathepsin S in coronary lesions. International Journal of Cardiology 215(): 506-515, 2016

Antibody targeting of Cathepsin S induces antibody-dependent cellular cytotoxicity. Molecular Cancer 10: 147-147, 2013

Characterization of an ITP patient-derived anti-alpha2bbeta3 monoclonal antibody that inhibits platelet aggregation. Blood 102(11): 87a, November 16, 2003

IgA monoclonal antibody of an ALS patient that recognizes NFH and a 65-kD neuronal protein inhibits phosphorylation of NFH by cdc2 kinase in vitro. Neurology 45(4 SUPPL 4): A221, 1995